H.R. 9190

119 HR 9190 IH: Right to Try for Individualized Treatments Act
 U.S. House of Representatives
 2026-06-08
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  2d Session  H. R. 9190  IN THE HOUSE OF REPRESENTATIVES   June 8, 2026   Mrs. Harshbarger  (for herself and  Mr. Biggs of Arizona ) introduced the following bill; which was referred to the  Committee on Energy and Commerce    A BILL
To amend the Federal Food, Drug, and Cosmetic Act to authorize the use of investigational individualized medical treatments by patients diagnosed with a life-threatening disease or condition or severely debilitating illness, and for other purposes.
1.
Short title
This Act may be cited as the   Right to Try for Individualized Treatments Act  .
2.
Use of investigational individualized medical treatments by patients diagnosed with a life-threatening disease or condition or severely debilitating illness
(a)
Definitions
Section 561B(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–0a(a)) is amended—
(1)
by amending paragraph (1) to read as follows:
(1)
the term  eligible patient  means—
(A)
in the case of a patient requesting an eligible investigational drug, a patient who has—
(i)
been diagnosed with a life-threatening disease or condition (as defined in section 312.81 of title 21, Code of Federal Regulations (or any successor regulations));
(ii)
exhausted approved treatment options and is unable to participate in a clinical trial involving the eligible investigational drug, as certified by a physician, who—
(I)
is in good standing with the physician’s licensing organization or board; and
(II)
will not be compensated directly by the manufacturer of such drug for so certifying; and
(iii)
provided to the treating physician written informed consent regarding the eligible investigational drug, or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent; or
(B)
in the case of a patient requesting an investigational individualized medical treatment, a patient who has—
(i)
been diagnosed with a life-threatening disease or condition or severely debilitating illness (as such terms are defined in section 312.81 of title 21, Code of Federal Regulations (or any successor regulations));
(ii)
considered approved treatment options, as certified by a physician, who—
(I)
is in good standing with the physician’s licensing organization or board;
(II)
will not be compensated directly by the manufacturer of such treatment for so certifying; and
(III)
attests to the patient’s life-threatening disease or condition or severely debilitating illness; and
(iii)
provided to the treating physician—
(I)
written informed consent regarding the eligible investigational drug or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent; or
(II)
as applicable, additional informed consent, regarding the investigational individualized medical treatment, or, as applicable, on whose behalf a legally authorized representative of the patient has provided such consent;
 ;
(2)
in paragraph (2)(D), by striking  and  at the end;
(3)
in paragraph (3), by striking the period at the end and inserting a semicolon; and
(4)
by adding at the end the following:
(4)
the term  eligible health care facility  means a health care facility that is operating under the Federal assurance for protection of human subjects pursuant to section 491(a) of the Public Health Service Act;
(5)
the term  investigational individualized medical treatment  means a drug or biological product for the patient based on an analysis of the patient’s unique genomic profile, including their genomic sequence, human chromosomes, deoxyribonucleic acid, genes, gene products (such as enzymes and other types of proteins), or metabolites; and
(6)
the term  additional informed consent  means consent attested to in writing by the patient’s physician and a witness for an investigational individualized medical treatment that includes—
(A)
an explanation of the currently approved treatments for the patient’s disease or condition;
(B)
the patient’s attestation that the patient concurs with the assessment of their physician that all currently approved and conventionally recognized treatments are unlikely to prolong or improve their life;
(C)
clear identification of the specific proposed investigational individualized medical treatment the patient’s physician recommends; and
(D)
a description, based on the physician’s knowledge of the proposed treatment and the patient’s disease, of the potential outcomes of the treatment.
 .
(b)
Eligibility for investigational individualized medical treatment
Section 561B of such Act ( 21 U.S.C. 360bbb–0a ) is amended—
(1)
by redesignating subsections (b) through (d) as subsections (c) through (e), respectively; and
(2)
by inserting after subsection (a) the following:
(b)
Eligibility for investigational individualized medical treatment
A manufacturer of an investigational individualized medical treatment that is in compliance with all applicable Federal assurance laws and regulations and is operating within an eligible health care facility may make available such investigational individualized medical treatment, and an eligible patient may request access to such treatment from the eligible health care facility or manufacturer of such treatment, consistent with the requirements of this section. A manufacturer of an investigational individualized medical treatment is not required to make available such treatment to any patient.
 .
(c)
Exemptions
Section 561B(c) of such Act (21 U.S.C. 360bbb–0a(c)), as redesignated by subsection (b)(1) of this section, is amended—
(1)
by inserting  and investigational individualized medical treatments  after  Eligible investigational drugs ;
(2)
by inserting  or investigational individualized medical treatment  after  such eligible investigational drug ;
(3)
by inserting  or investigational individualized medical treatment  after  an eligible investigational drug ; and
(4)
by inserting  or investigational individualized medical treatments  after  investigational drugs .
(d)
Conforming amendments
Section 561B of such Act ( 21 U.S.C. 360bbb–0a ) is amended—
(1)
in the section heading, by inserting
and investigational individualized medical treatments   after
drugs  ; and
(2)
in subsection (e)(2), as redesignated by subsection (b)(1) of this section—
(A)
in subparagraph (A), by striking  subsection (c)(1)(A)  and inserting  subsection (d)(1)(A) ; and
(B)
in subparagraph (B), by striking  subsection (c)(1)(B)  and inserting  subsection (d)(1)(B) .